ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Mochida Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 5.66%
- The company has been able to generate a Return on Equity (avg) of 5.66% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with a -6.29% CAGR growth in Operating Profits over the last 5 years
- The company has been able to generate a Return on Equity (avg) of 5.66% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 1.76% and Operating profit at -6.29% over the last 5 years
4
Positive results in Jun 26
- ROCE(HY) Highest at 6.77%
- INVENTORY TURNOVER RATIO(HY) Highest at 1.84 times
- DEBTORS TURNOVER RATIO(HY) Highest at 3.63 times
5
With ROE of 4.67%, it has a attractive valuation with a 0.83 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 0.47%, its profits have risen by 7% ; the PEG ratio of the company is 1.7
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Mochida Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Mochida Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Mochida Pharmaceutical Co., Ltd.
0.47%
0.17
24.80%
Japan Nikkei 225
60.14%
2.05
29.37%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.76%
EBIT Growth (5y)
-6.29%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.80
Tax Ratio
29.25%
Dividend Payout Ratio
35.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.05%
ROE (avg)
5.66%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
0.83
EV to EBIT
9.78
EV to EBITDA
7.23
EV to Capital Employed
0.78
EV to Sales
0.73
PEG Ratio
1.74
Dividend Yield
NA
ROCE (Latest)
7.94%
ROE (Latest)
4.67%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
ROCE(HY)
Highest at 6.77%
INVENTORY TURNOVER RATIO(HY)
Highest at 1.84 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.63 times
NET SALES(Q)
At JPY 31,719 MM has Grown at 19.11%
OPERATING PROFIT(Q)
Highest at JPY 4,295 MM
OPERATING PROFIT MARGIN(Q)
Highest at 13.54 %
PRE-TAX PROFIT(Q)
Highest at JPY 4,866 MM
NET PROFIT(Q)
Highest at JPY 3,178 MM
EPS(Q)
Highest at JPY 89.75
-11What is not working for the Company
INTEREST(HY)
At JPY 85 MM has Grown at 8,400%
RAW MATERIAL COST(Y)
Grown by 9.69% (YoY
CASH AND EQV(HY)
Lowest at JPY 59,464 MM
DEBT-EQUITY RATIO
(HY)
Highest at -12.54 %
Here's what is working for Mochida Pharmaceutical Co., Ltd.
Net Sales
At JPY 31,719 MM has Grown at 19.11%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 4,295 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 13.54 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 4,866 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Pre-Tax Profit
At JPY 4,866 MM has Grown at 74.91%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 3,178 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Net Profit
At JPY 3,178 MM has Grown at 67.79%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 89.75
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Inventory Turnover Ratio
Highest at 1.84 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.63 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Mochida Pharmaceutical Co., Ltd.
Interest
At JPY 85 MM has Grown at 8,400%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Cash and Eqv
Lowest at JPY 59,464 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -12.54 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 9.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Non Operating Income
Highest at JPY 0.28 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
